A Phase 3 interventional study of Imatinib and Sildenafil in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-21.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one is the 11th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 3, and was the 13th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:
Silvia Ulrich · Sites in Switzerland
Ages 18–80
By country, each count listing its studies:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 8 · Phase 4 6
First in 2002; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 23 across the 18 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
12 studies in Pulmonary Arterial Hypertension by Novartis: 1 open now, 1 under way, none of them phase 3. Of 11 finished, 11 (100%) have results posted.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 8th largest by enrollment, is one of 2 that started in 2011, is one of 5 in phase 3, and was the 5th registered.
Novartis’s Pulmonary Arterial Hypertension studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 12 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received treatment with bosentan 125 milligrams (mg) twice daily and sildenafil thrice daily for 8 days in treatment period 1. Participants were on the same sildenafil dose level (20, 40, 50 or 60 mg) they had been at study entry which was well tolerated in conjunction with bosentan. Following treatment period 1, the participants received concomitant treatment of oral imatinib 200 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 2. Following treatment period 2, the participants received concomitant treatment of oral imatinib 400 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 3.
Drug: Imatinib · Drug: Sildenafil · Drug: Bosentan
Film coated tablets, oral administration
Also known as: QTI571
Oral Administration
Oral Administration
Geometric Mean Ratio of Dose Normalized Area Under the Curve From Time Zero to Tau (AUCtau) for Bosentan Before and After Imatinib Administrations
AUCtau was the area under the curve calculated to the end of the dosing interval, tau. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of bosentan was performed on dose normalized AUCtau of bosentan. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).
Time frame: Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
Geometric Mean Ratio of Dose Normalized AUCtau for Sildenafil Before and After Imatinib Administrations
AUCtau was the area under the curve calculated to the end of the dosing interval, tau. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of sildenafil was performed on dose normalized AUCtau of sildenafil. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).
Time frame: Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
Geometric Mean Ratio of Dose Normalized Maximum Plasma Concentration (Cmax) for Bosentan Before and After Imatinib Administrations
Cmax was the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after dose administration. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of bosentan was performed on dose normalized Cmax of bosentan. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).
Time frame: Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
Geometric Mean Ratio of Dose Normalized Cmax for Sildenafil Before and After Imatinib Administrations
Cmax was the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after dose administration. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of sildenafil was performed on dose normalized Cmax of sildenafil. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals was then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).
Time frame: Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
Number of Participants With At Least One or More Adverse Events (AEs)
An adverse event was the appearance or worsening of any undesirable sign, symptom, or medical condition that occurred after starting the study drug even if the event was not considered to be related to study drug. Number of participants with AEs were reported by treatment period.
Time frame: From time of first administration of study drug until end of study (up to approximately 18 months)
Dose Normalized Cmax of Imatinib and CGP74588 (Active Metabolite of Imatinib)
Time frame: Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
Dose Normalized AUCtau of Imatinib and CGP74588 (Active Metabolite of Imatinib)
Time frame: Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
Participants with pulmonary arterial hypertension (PAH) were enrolled in the study at 8 investigation sites worldwide from 20 April 2011 to 25 October 2012.
| Milestone | Imatinib+ Bosentan+ Sildenafil |
|---|---|
| Started | 21 |
| Completed | 17 |
| Not completed | 4 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Protocol violation | 1 |
AUCtau was the area under the curve calculated to the end of the dosing interval, tau. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of bosentan was performed on dose normalized AUCtau of bosentan. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).
| hr*ng/mL/mg | Bosentan + Sildenafil (Reference) | Imatinib (200 mg/Day) + Bosentan + Sildenafil (Test 1) | Imatinib (400 mg/Day) + Bosentan + Sildenafil (Test 2) |
|---|---|---|---|
| Geometric Mean Ratio of Dose Normalized Area Under the Curve From Time Zero to Tau (AUCtau) for Bosentan Before and After Imatinib Administrations | 93.3 ± 49.9 | 109 ± 52.0 | 131 ± 38.0 |
AUCtau was the area under the curve calculated to the end of the dosing interval, tau. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of sildenafil was performed on dose normalized AUCtau of sildenafil. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).
| hr*ng/mL/mg | Bosentan + Sildenafil (Reference) | Imatinib (200 mg/Day) + Bosentan + Sildenafil (Test 1) | Imatinib (400 mg/Day) + Bosentan + Sildenafil (Test 2) |
|---|---|---|---|
| Geometric Mean Ratio of Dose Normalized AUCtau for Sildenafil Before and After Imatinib Administrations | 7.22 ± 60.6 | 9.82 ± 42.5 | 12.3 ± 40.9 |
Cmax was the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after dose administration. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of bosentan was performed on dose normalized Cmax of bosentan. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).
| ng/mL/mg | Bosentan + Sildenafil (Reference) | Imatinib (200 mg/Day) + Bosentan + Sildenafil (Test 1) | Imatinib (400 mg/Day) + Bosentan + Sildenafil (Test 2) |
|---|---|---|---|
| Geometric Mean Ratio of Dose Normalized Maximum Plasma Concentration (Cmax) for Bosentan Before and After Imatinib Administrations | 21.9 ± 48.8 | 21.8 ± 60.3 | 23.4 ± 44.7 |
Cmax was the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after dose administration. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of sildenafil was performed on dose normalized Cmax of sildenafil. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals was then "back-transformed" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference).
| ng/mL/mg | Bosentan + Sildenafil (Reference) | Imatinib (200 mg/Day) + Bosentan + Sildenafil (Test 1) | Imatinib (400 mg/Day) + Bosentan + Sildenafil (Test 2) |
|---|---|---|---|
| Geometric Mean Ratio of Dose Normalized Cmax for Sildenafil Before and After Imatinib Administrations | 2.44 ± 68.6 | 3.14 ± 52.4 | 3.81 ± 52.9 |
An adverse event was the appearance or worsening of any undesirable sign, symptom, or medical condition that occurred after starting the study drug even if the event was not considered to be related to study drug. Number of participants with AEs were reported by treatment period.
| Participants | Bosentan + Sildenafil | Imatinib (200 mg/Day) + Bosentan + Sildenafil | Imatinib (400 mg/Day) + Bosentan+ Sildenafil |
|---|---|---|---|
| Number of Participants With At Least One or More Adverse Events (AEs) | 10 | 9 | 16 |
| ng/ml/mg | Imatinib (200 mg/Day) + Bosentan + Sildenafil | Imatinib (400 mg/Day) + Bosentan + Sildenafil |
|---|---|---|
| Imatinib Cmax/Dose | 7.55 ± 4.18 | 6.71 ± 3.39 |
| CGP74588 Cmax/Dose | 1.37 ± 0.538 | 1.39 ± 0.575 |
| hr*ng/mL/mg | Imatinib (200 mg/Day) + Bosentan + Sildenafil | Imatinib (400 mg/Day) + Bosentan + Sildenafil |
|---|---|---|
| Imatinib AUCtau/Dose | 90.9 ± 49.3 | 88.4 ± 36.0 |
| CGP74588 AUCtau/Dose | 19.3 ± 9.69 | 20.6 ± 9.07 |
Collected over From time of first administration of study drug until end of study (up to approximately 18 months). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bosentan + Sildenafil | 0/21 (0%) | 0/21 (0%) | 10/21 (47.6%) |
| Imatinib (200 mg/Day) + Bosentan + Sildenafil | 0/19 (0%) | 2/19 (10.5%) | 9/19 (47.4%) |
| Imatinib (400 mg/Day) + Bosentan+ Sildenafil | 0/18 (0%) | 1/18 (5.6%) | 16/18 (88.9%) |
| Total Participants | 0/21 (0%) | 2/21 (9.5%) | 19/21 (90.5%) |
| Event | Bosentan + Sildenafil | Imatinib (200 mg/Day) + Bosentan + Sildenafil | Imatinib (400 mg/Day) + Bosentan+ Sildenafil | Total Participants |
|---|---|---|---|---|
| Atrial flutterCardiac disorders | 0/21 | 0/19 | 1/18 | 1/21 |
| RashSkin and subcutaneous tissue disorders | 0/21 | 0/19 | 1/18 | 1/21 |
| Cardiac failure congestiveCardiac disorders | 0/21 | 1/19 | 0/18 | 1/21 |
| Viral infectionInfections and infestations | 0/21 | 1/19 | 0/18 | 1/21 |
| Event | Bosentan + Sildenafil | Imatinib (200 mg/Day) + Bosentan + Sildenafil | Imatinib (400 mg/Day) + Bosentan+ Sildenafil | Total Participants |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/21 | 5/19 | 2/18 | 7/21 |
| NauseaGastrointestinal disorders | 1/21 | 4/19 | 2/18 | 7/21 |
| VomitingGastrointestinal disorders | 0/21 | 1/19 | 4/18 | 5/21 |
| Oedema peripheralGeneral disorders | 2/21 | 1/19 | 3/18 | 5/21 |
| AnaemiaBlood and lymphatic system disorders | 1/21 | 1/19 | 3/18 | 4/21 |
| Blood potassium decreasedInvestigations | 0/21 | 1/19 | 3/18 | 4/21 |
| HeadacheNervous system disorders | 1/21 | 2/19 | 1/18 | 4/21 |
| DizzinessNervous system disorders | 3/21 | 0/19 | 0/18 | 3/21 |
| Urinary tract infectionInfections and infestations | 0/21 | 0/19 | 2/18 | 2/21 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/21 | 0/19 | 2/18 | 2/21 |
Safety analysis set included all participants enrolled and who received at least one dose of study drug (bosentan, sildenafil, or imatinib).
| Age, Continuous(years) | Imatinib+ Bosentan+ Sildenafil |
|---|---|
| Mean | 54.4 ± 13.44 |
| Sex: Female, Male(Participants) | Imatinib+ Bosentan+ Sildenafil |
|---|---|
| Female | 15 |
| Male | 6 |
Ran from Apr 2011 to primary completion in Oct 2012, 18 months.
Results were first posted in Jun 2021, 8 years 7 months after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 18 months is below that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Imatinib · Sildenafil · Bosentan
Pulmonary Arterial Hypertension →